Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06107062 · ClinicalTrials.gov registry record · Phase 2
Longitudinal Outpatient Treatment for Cannabis Use Disorder
A Phase 2 study of Cannabis Use Disorder, sponsored by University of Colorado, Boulder.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
- 1
- Study location
NCT06107062: Recruiting Phase 2 study of Cannabis Use Disorder, sponsored by University of Colorado, Boulder.
NCT06107062 is a Phase 2 study of Cannabis Use Disorder that is actively recruiting participants, run by University of Colorado, Boulder. The registered enrollment target is 165 participants, above the 104-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (59% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06107062, a Phase 2 study of Cannabis Use Disorder, is actively recruiting participants, sponsored by University of Colorado, Boulder.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a placebo-controlled randomized trial comparing the effects of hemp-derived cannabidiol (CBD) with and without Delta-9-tetrahydrocannabinol (THC), relative to placebo, on reducing cannabis use and cannabis use disorder (CUD) symptoms in adult treatment seeking cannabis concentrate users with CUD. Participants enroll in the study for 8 weeks (with telehealth follow-ups at 12 and 16 weeks) and are randomized to either full spectrum CBD, broad spectrum CBD, or placebo. Participants are also engaged in five weeks of psychotherapy treatment for CUD. Blood is collected to quantify investigational drug exposure and cannabis use. Participants also complete self-report measures of medical history, sleep quality, subjective cognitive function, physical activity, psychological functioning, substance use, and acute drug effects.
Primary Outcome
The change in the amount of cannabis used by participants as measured by self-report
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cannabidiol - fsCBD
- DRUG Cannabidiol - bsCBD
Study Locations (1)
Colorado
- University of Colorado Boulder - Boulder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2024-05-16 |
| Est. Completion | 2029-03-31 |
| Phase | Phase 2 |
What NCT06107062 shows while recruiting
NCT06107062 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, above the 104-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (59% higher).
The record links to 1 condition, with Cannabis Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06107062 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06107062 about?
NCT06107062 is a clinical study titled "Longitudinal Outpatient Treatment for Cannabis Use Disorder". This study is a placebo-controlled randomized trial comparing the effects of hemp-derived cannabidiol (CBD) with and without Delta-9-tetrahydrocannabinol (THC), relative to placebo, on reducing cannabis use and cannabis use disorder (CUD) symptoms in adult treatment seeking cannabis concentrate user...
What is the current status of trial NCT06107062?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2024-05-16. Estimated completion is 2029-03-31.
What conditions does trial NCT06107062 study?
This clinical trial studies the following conditions: Cannabis Use Disorder.
What interventions are being tested in trial NCT06107062?
The interventions under investigation include: Placebo (DRUG), Cannabidiol - fsCBD (DRUG), Cannabidiol - bsCBD (DRUG).
Who is sponsoring clinical trial NCT06107062?
This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06107062 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06107062's enrollment target sits among peer trials
165 11th of 34 higher than 24 of 34 other Cannabis Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cannabidiol in Young Adult Cannabis Users
RECRUITING · Phase 2
-
Effects of THC on Alcohol Consumption and Neural Correlates of Reward
RECRUITING · Phase 2
-
Cannabidiol and Cannabis Concentrate Users
RECRUITING · Phase 2
-
A Teleheath tDCS Approach to Decrease Cannabis Use
COMPLETED · Phase 2
-
Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder
COMPLETED · Phase 2
-
UH3 Varenicline for Cannabis Use Disorder
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI